Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options

Thumbnail
Ver/abrir
Use este enlace para citar
http://hdl.handle.net/2183/32966
Creative Commons Attribution 3.0 International License (CC-BY 3.0)
A non ser que se indique outra cousa, a licenza do ítem descríbese como Creative Commons Attribution 3.0 International License (CC-BY 3.0)
Coleccións
Metadatos
Mostrar o rexistro completo do ítem
Título
Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options
Autor(es)
Data
2010-01-12
Cita bibliográfica
Isidro ML, Cordido F. Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options. Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145.
Resumo
[Abstract] Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options.
Palabras chave
Drug treatment
Ghrelin
Leptin
Obesity
Orlistat
Sibutramine
Rimonabant
 
Descrición
Review
Versión do editor
Dereitos
Creative Commons Attribution 3.0 International License (CC-BY 3.0)
ISSN
1424-8247